Market Movers (8-K)
See all →Crescent Biopharma announced Q2 2026 financial results, highlighting progress in its clinical trials for CR-001, CR-002, and CR-003, and a strengthened cash position extending runway into late 2028.
Capital raise
Crescent Biopharma announced the pricing of its public offering of ordinary shares and pre-funded warrants, expecting to raise approximately $125 million.
Capital raise
Crescent Biopharma, Inc. announced preliminary unaudited financial information, estimating cash and cash equivalents of approximately $171.6 million as of June 30, 2026.
Crescent Biopharma, Inc. held its annual meeting on June 2, 2026, where shareholders elected directors, ratified the auditor, and approved executive compensation.
Crescent Biopharma announced its Q4 and full-year 2025 financial results, highlighting a strategic partnership with Kelun-Biotech, significant clinical trial advancements, and a $185 million private placement.
Capital raise
Crescent Biopharma announced a strategic partnership with Kelun-Biotech and a $185 million private placement to accelerate its oncology pipeline, including three programs entering clinical trials in 2026.
Better than expected
Capital raise
Quarterly Earnings (10-Q)
See all →Crescent Biopharma, Inc. (NASDAQ: CBIO) filed its Form 10-Q for the quarter ended June 30, 2026, detailing its financial performance and ongoing clinical development activities.
Worse than expected
Capital raise
Crescent Biopharma, a preclinical-stage biotechnology company, reported significant operating losses for Q3 2025 while advancing its lead oncology programs CR-001, CR-002, and CR-003.
Capital raise
Crescent Biopharma, a preclinical-stage biotechnology company, reported a net loss of $21.8 million for Q2 2025 and $36.9 million for the first six months of 2025, while highlighting its strategic reverse recapitalization and focus on advancing its oncology pipeline, particularly lead program CR-001.
Worse than expected
Capital raise
GlycoMimetics reports Q1 2025 results, highlighting a net loss and ongoing efforts to finalize a merger with Crescent Biopharma amidst concerns about its ability to continue as a going concern.
Capital raise
Worse than expected
GlycoMimetics, Inc. has entered into a merger agreement with Crescent Biopharma, Inc., following a strategic review and significant workforce reduction, while also reporting its Q3 2024 financial results.
Worse than expected
Capital raise
10-Q: GlycoMimetics Faces Uncertain Future After Uproleselan Trial Setback, Initiates Strategic Review
GlycoMimetics is conducting a strategic review of its business after a Phase 3 trial of its lead drug candidate, uproleselan, failed to meet its primary endpoint, leading to an 80% workforce reduction.
Worse than expected
Capital raise
Annual Reports (10-K)
Crescent Biopharma details its oncology pipeline, strategic partnerships, and financial position in its 2025 annual report, highlighting significant capital raises and ongoing clinical development.
Capital raise
GlycoMimetics plans to merge with Crescent Biopharma following a strategic review prompted by disappointing clinical trial results, aiming to maximize shareholder value.
Worse than expected
Capital raise
GlycoMimetics, Inc. released its annual report on Form 10-K, detailing its financial performance and progress in drug development for the fiscal year ended December 31, 2023.
Worse than expected
Capital raise
Insider Trading (Form 4)
See all →Fairmount Funds Management LLC and 3 others reported changes in beneficial ownership of Glycomimetics Inc common stock on July 16, 2026.
Crescent Biopharma, Inc. director Jonathan Violin was granted 11,050 stock options as part of his compensation package.
Director David Charles Lubner was granted 11,050 stock options in Crescent Biopharma, Inc. as part of his compensation.
Director Alexandra Balcom was granted 11,050 stock options in Crescent Biopharma, Inc. as part of a standard equity incentive.
Director Susan Moran was granted 11,050 stock options in Crescent Biopharma, Inc. as part of a standard equity compensation arrangement.
Fairmount Funds Management and associated directors were granted 11,050 stock options in Crescent Biopharma, Inc.
Proxy Statements (Def-14A)
Crescent Biopharma, Inc. has announced its 2026 Annual General Meeting of Shareholders, scheduled for June 2, 2026, to be held virtually.
Capital raise
GlycoMimetics and Crescent Biopharma updated their investor presentation regarding their proposed merger, highlighting Crescent's oncology pipeline and potential.
GlycoMimetics and Crescent Biopharma updated their investor presentation regarding their proposed merger on November 7, 2024, highlighting Crescent's pipeline and potential.
DEFA14A: GlycoMimetics to Acquire Crescent Biopharma in All-Stock Deal, Secures $200 Million Financing
GlycoMimetics will acquire Crescent Biopharma, pivoting to solid tumor therapeutics with a $200 million financing to advance Crescent's pipeline.
Worse than expected
Capital raise
DEF 14A: GlycoMimetics Seeks Stockholder Approval for Increased Share Authorization and Officer Exculpation
GlycoMimetics is holding its annual stockholder meeting on May 1, 2024, to vote on key proposals including director elections, auditor ratification, executive compensation, increasing authorized shares, and officer exculpation.
Capital raise
New Public Companies (S-1)
Crescent Biopharma announces strategic partnerships with Kelun-Biotech and Paragon Therapeutics, securing $100 million in upfront payments and advancing its oncology pipeline with CR-001, CR-002, and SKB105 (CR-003) towards Phase 1/2 trials in 2026.
Capital raise
Schedule 13D - Activist Investments
Fairmount Funds Management LLC and its affiliates have increased their beneficial ownership in Crescent Biopharma, Inc. to 16.52% through recent share and warrant purchases.
Capital raise
Fairmount Funds Management LLC and its affiliates increased their beneficial ownership in Crescent Biopharma, Inc. to 18.53% through a $20 million private placement.
Capital raise
Fairmount Funds Management LLC and its affiliates have disclosed a significant 19.99% beneficial ownership in Crescent Biopharma, Inc. following the recent merger and associated financing activities, including a $44 million investment.
Capital raise
SCHEDULE 13D/A: Adage Capital Reduces Stake in GlycoMimetics (Now Crescent Biopharma) Below 5% Threshold Following Corporate Restructuring
Adage Capital Management, L.P. and its principals have filed an Amendment to their Schedule 13D, indicating their beneficial ownership in GlycoMimetics Inc. (now Crescent Biopharma, Inc.) has fallen below 5% following a merger, reverse stock split, and redomestication, leading to their voluntary exit from the reporting system.
Schedule 13G - Passive Investments
See all →Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5.48% of Crescent Biopharma, Inc. common stock as of March 31, 2026.
FMR LLC and Abigail P. Johnson have disclosed a 15.0% beneficial ownership stake in Crescent Biopharma Inc. common stock as of December 31, 2025.
Forbion Growth III PA B.V. and affiliated entities have reported a 6.1% beneficial ownership stake in Crescent Biopharma, Inc. following a recent private placement.
Capital raise
1Globe Capital LLC and Chairman Jiaqiang Li have reported a 10.3% beneficial ownership stake in Crescent Biopharma, Inc. ordinary shares.
Tang Capital Management and affiliates report a 5.04% beneficial ownership in Crescent Biopharma, Inc., holding 700,000 ordinary shares.
1Globe Capital LLC and its Chairman, Jiaqiang Li, have disclosed a passive beneficial ownership of 6.45% in Crescent Biopharma, Inc., totaling 896,712 ordinary shares.